Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Fagan

Showing results (91-100 of 260) with videos related to

Pageof 26
Sort By:
Clinical Pharmacology and Therapeutics|September 1, 1986
Antihypertensive and biochemical dose-response study of tripamideT C Fagan, K A Conrad, S Lee, et al.
Neurochemical Research|August 9, 2018
Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral IschemiaTauheed Ishrat, Sahar Soliman, Wael Eldahshan, et al.
Journal of Cardiovascular Pharmacology|January 1, 1984
Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapyT C Fagan, C Sternleib, N Vlachakis, et al.
European Journal of Pharmacology|February 14, 2017
Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injuryAbdelrahman Y Fouda, Bindu Pillai, Krishnan M Dhandapani, et al.
Translational Stroke Research|June 5, 2013
Recommendations for preclinical research in hemorrhagic transformationSusan C Fagan, Paul A Lapchak, David S Liebeskind, et al.
Pharmacotherapy|January 27, 2010
Diverse effects of statins on angiogenesis: new therapeutic avenuesHazem F Elewa, Azza B El-Remessy, Payaningal R Somanath, et al.
Foods (Basel, Switzerland)|February 26, 2025
Impact of Selected Starters and Cassava Varieties on the Proximate, Rheological, and Volatile Profiles of LafunAbosede O Fawole, Kimon-Andreas G Karatzas, Jane K Parker, et al.
The Annals of Pharmacotherapy|February 11, 2000
The effect of intravenous verapamil on cerebral hemodynamics in a migraine patient with hemiplegiaT M Ng, A Kohli, S C Fagan, et al.
Drugs in R&D|May 18, 2019
Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USAStephanie V Phan, Sharmon Osae, John C Morgan, et al.
Journal of the American Pharmacists Association : Japha|April 21, 2004
New perspectives on the pharmacotherapy of ischemic strokeJ Chris Bradberry, Susan C Fagan, David R Gray, et al.
Pageof 26

Showing results (91-100 of 260) with videos related to

Sort By:
Pageof 26
Clinical Pharmacology and Therapeutics|September 1, 1986
Antihypertensive and biochemical dose-response study of tripamideT C Fagan, K A Conrad, S Lee, et al.
Neurochemical Research|August 9, 2018
Silencing VEGF-B Diminishes the Neuroprotective Effect of Candesartan Treatment After Experimental Focal Cerebral IschemiaTauheed Ishrat, Sahar Soliman, Wael Eldahshan, et al.
Journal of Cardiovascular Pharmacology|January 1, 1984
Efficacy and safety comparison of nitrendipine and hydralazine as antihypertensive monotherapyT C Fagan, C Sternleib, N Vlachakis, et al.
European Journal of Pharmacology|February 14, 2017
Role of interleukin-10 in the neuroprotective effect of the Angiotensin Type 2 Receptor agonist, compound 21, after ischemia/reperfusion injuryAbdelrahman Y Fouda, Bindu Pillai, Krishnan M Dhandapani, et al.
Translational Stroke Research|June 5, 2013
Recommendations for preclinical research in hemorrhagic transformationSusan C Fagan, Paul A Lapchak, David S Liebeskind, et al.
Pharmacotherapy|January 27, 2010
Diverse effects of statins on angiogenesis: new therapeutic avenuesHazem F Elewa, Azza B El-Remessy, Payaningal R Somanath, et al.
Foods (Basel, Switzerland)|February 26, 2025
Impact of Selected Starters and Cassava Varieties on the Proximate, Rheological, and Volatile Profiles of LafunAbosede O Fawole, Kimon-Andreas G Karatzas, Jane K Parker, et al.
The Annals of Pharmacotherapy|February 11, 2000
The effect of intravenous verapamil on cerebral hemodynamics in a migraine patient with hemiplegiaT M Ng, A Kohli, S C Fagan, et al.
Drugs in R&D|May 18, 2019
Neuropsychiatric Symptoms in Dementia: Considerations for Pharmacotherapy in the USAStephanie V Phan, Sharmon Osae, John C Morgan, et al.
Journal of the American Pharmacists Association : Japha|April 21, 2004
New perspectives on the pharmacotherapy of ischemic strokeJ Chris Bradberry, Susan C Fagan, David R Gray, et al.
Pageof 26